Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer

被引：0

作者：

Shah, Manasee V. ^{[1
]}

Solem, Caitlyn T. ^{[1
]}

Bell, Kelly F. ^{[1
]}

Aziez, Amine ^{[2
]}

Sun, Xuezheng ^{[3
]}

Du, Mandy ^{[4
]}

Du, Ella X. ^{[4
]}

Yang, Hongbo ^{[4
]}

Wang, Hongjue ^{[5
]}

Hua, Qi ^{[4
]}

Tapan, Umit ^{[6
,7
]}

机构：

[1] GSK, Collegeville, PA USA

[2] GSK, Basel, Switzerland

[3] GSK, Res Triangle Pk, NC USA

[4] Anal Grp Inc, Boston, MA USA

[5] Anal Grp Inc, London, England

[6] Boston Univ, Chobanian & Avedisian Sch Med, Sect Hematol & Med Oncol, 820 Harrison Ave, Boston, MA 02118 USA

[7] Boston Med Ctr, 820 Harrison Ave, Boston, MA 02118 USA

来源：

ADVANCES IN THERAPY | 2025年 / 42卷 / 06期

关键词：

Non-small cell lung cancer; Real-world; Maintenance therapy; Immunotherapy; PD-L1; Non-squamous;

D O I：

10.1007/s12325-025-03178-8

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

IntroductionImmuno-oncology (IO) agents and pemetrexed are approved for the first-line (1L) maintenance treatment (1LMT) of advanced/metastatic non-small cell lung cancer (a/mNSCLC). This international retrospective chart review assessed real-world treatment patterns and outcomes in patients with a/mNSCLC lacking targetable mutations. MethodsOncologists from seven countries (Canada, France, Germany, Italy, Spain, UK, USA) provided deidentified, medical chart-derived data on randomly selected adults with a/mNSCLC who remained stable or responded to 1L chemotherapy + IO. Treatment patterns, overall survival (OS), progression-free survival (PFS), and healthcare resource utilization (HCRU) were compared by maintenance treatment use following propensity score weighting. The effects of adding pemetrexed to IO-containing 1LMT was investigated in patients with non-squamous/mixed histology. ResultsOf 942 patients analyzed, 680 initiated 1LMT. After weighting, 1LMT was associated with longer median PFS (17.7 vs 7.1 months; HR [95% CI] 0.63 [0.41-0.85]), similar OS (31.7 vs 31.0 months; 0.82 [0.47-1.17]), and fewer mean monthly hospitalizations (0.03 vs 0.1; p < 0.01) versus no 1LMT. Among 469 patients with non-squamous/mixed histology who initiated an IO-containing 1LMT, 283 received IO only while 186 received IO + pemetrexed. Median time to treatment discontinuation (20.0 vs 11.0 months; p < 0.001), PFS (21.1 vs 11.1 months; HR [95% CI] 0.56 [0.37-0.76]), and OS (35.3 vs 27.3 months; 0.70 [0.41-0.98]) were longer for patients receiving IO only versus IO + pemetrexed. Fewer patients administered IO only experienced fatigue (28.3% vs 39.8% [IO + pemetrexed]; p < 0.05) and anemia (16.6% vs 31.2%; p < 0.001). Conclusion1LMT was associated with significantly longer PFS and similar OS, without substantially increasing HCRU, among the current study population with a/mNSCLC. Adding pemetrexed to 1LM IO did not confer significant clinical benefit in patients with non-squamous/mixed histology and these patients incurred more adverse events. Additional 1LMT options are needed to further improve clinical outcomes.

引用

页码：2782 / 2796

页数：15

共 15 条

[1] Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA [J].